

Appendix A: Letters of Support



Professor Stephen Faraone

President World Federation of ADHD Upstate Medical University
505 Irving Avenue Syracuse
New York

November 13, 2020

Dear Prof. Faraone:

On behalf of patients in Spain who receive treatment for ADHD I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines. Methylphenidate is a first line treatment for Attention Deficit Hyperactivity Disorder.

Patients with ADHD include children and adolescents as well as adults. Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 12 years. Children with ADHD have a significantly lower ability to focus and sustain attention and score higher on impulsivity and hyperactivity.

Untreated ADHD is not a benign condition and pharmacological interventions such as methylphenidate have wide ranging beneficial effects for Spanish patients. For most patients, the impairing symptoms of ADHD persist into adulthood. Because ADHD is a common neurodevelopment disorder in childhood affecting 5% of children and 2.8% of adults worldwide, limiting access to methylphenidate will have profound repercussions. It also does not consider the many mental and somatic health risks associated with failure to treat ADHD such as accidents, injuries, suicide, and premature death, which have been documented by large population studies or meta-analyses.

This medication has been a lifeline for so many thousands of children allowing them to access their education and very importantly to enjoy a positive family life. It has given them the opportunity to complete their education and move on into further education, university, and employment. All these experiences are crucial to a productive and secure future.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by prescribers. Ultimately it is the patient who then suffers.

Including methylphenidate on the List of Essential Medicines will go a long way to destigmatize a very real treatable condition and it will improve access to this very effective treatment which, in turn, will improve the quality of life of many people with ADHD and their relatives.

Yours sincerely

Josefina Rodriguez Sastre

President ARPANH

ARPANH

Asociación Riojana de Padres de Niños Hiperactivos

Avda. de La Rioja, 12, 2º, 26001 Logroño (La Rioja) Spain

www.arpanih.org

608 692 614 - arpanih@arpanih.org

Professor Stephen Faraone
President World Federation of ADHD Upstate Medical University
505 Irving Avenue Syracuse
New York

12 November 2020

Dear Prof. Faraone:

On behalf of patients in Spain who receive treatment for ADHD I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines. Methylphenidate is a first line treatment for Attention Deficit Hyperactivity Disorder.

Patients with ADHD includes children and adolescents as well as adults. Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 12 years. Children with ADHD have significantly lower ability to focus and sustain attention and score higher on impulsivity and hyperactivity.

Untreated ADHD is not a benign condition and pharmacological interventions such as methylphenidate have wide ranging beneficial effects for patients Spanish wide. For most patients, the impairing symptoms of ADHD persist into adulthood. Because ADHD is a common neurodevelopmental disorder in childhood affecting 5% of children and 2.8% of adults worldwide, limiting access to methylphenidate will have profound repercussions. It also does not consider the many mental and somatic health risks associated with failure to treat ADHD such as accidents, injuries, suicide, and premature death, which have been documented by large population studies or meta-analyses.

This medication has been a lifeline for so many thousands of children allowing them to access their education and very importantly to enjoy a positive family life. It has given them the opportunity to complete their education and move on into further education, university, and employment. All these experiences are crucial to a productive and secure future.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by prescribers. Ultimately it is the patient who then suffers.

Including methylphenidate on the List of Essential Medicines will go a long way to destigmatize a very real treatable condition and it will improve access to this very effective treatment which, in turn, will improve the quality of life of many people with ADHD and their relatives. Yours sincerely


ASOCIACION SOCIAL DE TDAH Y RETRASO
DE DESARROLLO DE MARBELLA-SAN PEDRO
ADAHIMAR
C.I.F.G-93286334
Fdo.: Vanesa Maeso Pizarro
Presidenta de ADAHIMAR

ADAHIMAR - Asociación de Ayuda al TDAH (Trastorno por Déficit de Atención/ Hiperactividad)
C/ Fernando VII, N° 44, Bq 5, 1° A. 29601. Marbella. (Málaga, España) Tlf. : +34 653590729
adahimar_tdah@yahoo.es <https://es-la.facebook.com/adahimar.sanpedro> adahimar.es



238, "Ta' Ganni", Triq il-Htajriet,

Mosta, MST 3067, Malta, Europe.

Mob: 77297800

Email : adhdmalta@gmail.com

www.adhdmalta.org.mt

www.facebook.com/ADHDMalta

11th November 2020

Dear Prof. Faraone,

On behalf of ADHD MALTA, I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children. Methylphenidate is a first line treatment for attention deficit hyperactivity disorder in MALTA. Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by the insurance programs that pay for medications. Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment which, in turn, will improve the quality of life of many children with ADHD and the parents that care for them.

Yours Sincerely,

Carla Stivala

Honorary Secretary

ADHD Malta (VO 41)



ASOCIACIÓN DE PERSONAS CON DEFICIT DE ATENCIÓN E HIPERACTIVIDAD DE BIZKAIA

Parque JM Txabarri Zuazo s/n Centro Gobelaurre 48930 Getxo (Bizkaia)

Tfno. 944 315 783 gtahida@gmail.com www.ahida.es

Professor Stephen Faraone
President World Federation of ADHD Upstate Medical University
505 Irving Avenue Syracuse
New York

13 November 2020

Dear Prof. Faraone:

On behalf of patients in Europe who receive treatment for ADHD I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines. Methylphenidate is a first line treatment for Attention Deficit Hyperactivity Disorder in all Bizkaia

Patients with ADHD includes children and adolescents as well as adults. Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 12 years. Children with ADHD have significantly lower ability to focus and sustain attention and score higher on impulsivity and hyperactivity.

Untreated ADHD is not a benign condition and pharmacological interventions such as methylphenidate have wide ranging beneficial effects for patients European wide. For most patients, the impairing symptoms of ADHD persist into adulthood. Because ADHD is a common neurodevelopmental disorder in childhood affecting 5% of children and 2.8% of adults worldwide, limiting access to methylphenidate will have profound repercussions. It also does not consider the many mental and somatic health risks associated with failure to treat ADHD such as accidents, injuries, suicide, and premature death, which have been documented by large population studies or meta-analyses.

This medication has been a lifeline for so many thousands of children allowing them to access their education and very importantly to enjoy a positive family life. It has given them the opportunity to complete their education and move on into further education, university, and employment. All these experiences are crucial to a productive and secure future.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by prescribers. Ultimately it is the patient who then suffers.

Including methylphenidate on the List of Essential Medicines will go a long way to destigmatize a very real treatable condition and it will improve access to this very effective treatment which, in turn, will improve the quality of life of many people with ADHD and their relatives.

Yours sincerely

Dr. Itziar Orive
President AHIDA Bizkaia



www.possibilitiesclinic.com
info@possibilitiesclinic.com
Toll Free: 1-833-482-5558
Fax : 1-833-482-8999

Dear Prof. Faraone:

I would like to express my strong support for the inclusion of methylphenidate on the World Health Organization's List of Essential Medicines for Children. ADHD causes significant morbidity for children and adolescents across the world. Methylphenidate is an extremely effective and first line treatment for ADHD, and is recognized as such by Canadian national guidelines, physician and healthcare organizations, the federal government and all provincial governments. If methylphenidate is not included on the List of Essential Medicine, this could affect decisions made by insurance companies and governmental agencies. It's essential for child mental health and quality of life that methylphenidate be included on the List of Essential Medicines ; otherwise this will reduce access and cause significant health issues to the children and families affected by this disorder. I thank you for you consideration of this important matter.

Doron Almagor MD FRCPC
Child and Adolescent Psychiatrist
Director, [Possibilities Clinic](http://www.possibilitiesclinic.com)

ADDISS

25 years of ADHD Advocacy

Professor Stephen Faraone
President World Federation of ADHD
Upstate Medical University
505 Irving Avenue
Syracuse
New York

8 November 2020

Dear Prof. Faraone:

On behalf of parents and children in the UK who receive treatment for ADHD I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children. Methylphenidate is a first line treatment for Attention Deficit Hyperactivity Disorder in the United Kingdom as recommended in the NICE Guidelines (National Institute of Health and Clinical Excellence). This medication has been a lifeline for so many thousands of children allowing them to access their education and very importantly to enjoy a positive family life. It has given them the opportunity to complete their education and move on into further education, university and employment. All these experiences are crucial to a productive and secure future.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by prescribers. Ultimately it is the patient who then suffers.

Including methylphenidate on the List of Essential Medicines will go a long way to destigmatise a very real treatable condition and it will improve access to this very effective treatment which, in turn, will improve the quality of life of many children with ADHD and the parents that care for them.

Yours sincerely



Mrs Andrea Bilbow OBE
Founder and CEO of ADDISS
Vice President of ADHD Europe
ADDISS
10th Floor, Hyde House
The Hyde, Colindale
London NW9 6LH


ADDISS
ADHD INFORMATION SERVICES
Registered Charity No: 1070827

020 8952 2800
info@addiss.co.uk
addiss.co.uk



Professor Stephen Faraone
President World Federation of ADHD Upstate Medical University
505 Irving Avenue Syracuse
New York

12 November 2020

Dear Prof. Faraone:

On behalf of patients in Spain who receive treatment for ADHD I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines. Methylphenidate is a first line treatment for Attention Deficit Hyperactivity Disorder.

Patients with ADHD includes children and adolescents as well as adults. Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 12 years. Children with ADHD have significantly lower ability to focus and sustain attention and score higher on impulsivity and hyperactivity.

Untreated ADHD is not a benign condition and pharmacological interventions such as methylphenidate have wide ranging beneficial effects for patients Spanish wide. For most patients, the impairing symptoms of ADHD persist into adulthood. Because ADHD is a common neurodevelopmental disorder in childhood affecting 5% of children and 2.8% of adults worldwide, limiting access to methylphenidate will have profound repercussions. It also does not consider the many mental and somatic health risks associated with failure to treat ADHD such as accidents, injuries, suicide, and premature death, which have been documented by large population studies or meta-analyses.

This medication has been a lifeline for so many thousands of children allowing them to access their education and very importantly to enjoy a positive family life. It has given them the opportunity to complete their education and move on into further education, university, and employment. All these experiences are crucial to a productive and secure future.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by prescribers. Ultimately it is the patient who then suffers.

Including methylphenidate on the List of Essential Medicines will go a long way to destigmatize a very real treatable condition and it will improve access to this very effective treatment which, in turn, will improve the quality of life of many people with ADHD and their relatives.

Yours sincerely

María Parra Calderón
President ADAHIGI



ATIMANA-DAH
ASOCIACIÓN TDAH

**ASOCIACIÓN TINTERFEÑA DE MADRES Y PADRES DE NIÑOS Y
ADOLESCENTES CON DÉFICIT DE ATENCIÓN E HIPERACTIVIDAD**

Professor Stephen Faraone
President World Federation of ADHD Upstate Medical University
505 Irving Avenue Syracuse
New York

13th November 2020

Dear Prof. Faraone:

On behalf of patients in Spain who receive treatment for ADHD I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines. Methylphenidate is a first line treatment for Attention Deficit Hyperactivity Disorder.

Patients with ADHD includes children and adolescents as well as adults. Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 12 years. Children with ADHD have significantly lower ability to focus and sustain attention and score higher on impulsivity and hyperactivity.

Untreated ADHD is not a benign condition and pharmacological interventions such as methylphenidate have wide ranging beneficial effects for patients Spanish wide. For most patients, the impairing symptoms of ADHD persist into adulthood. Because ADHD is a common neurodevelopmental disorder in childhood affecting 5% of children and 2.8% of adults worldwide, limiting access to methylphenidate will have profound repercussions. It also does not consider the many mental and somatic health risks associated with failure to treat ADHD such as accidents, injuries, suicide, and premature death, which have been documented by large population studies or meta-analyses.

This medication has been a lifeline for so many thousands of children allowing them to access their education and very importantly to enjoy a positive family life. It has given them the opportunity to complete their education and move on into further education, university, and employment. All these experiences are crucial to a productive and secure future.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by prescribers. Ultimately it is the patient who then suffers.

Including methylphenidate on the List of Essential Medicines will go a long way to destigmatize a very real treatable condition and it will improve access to this very effective treatment which, in turn, will improve the quality of life of many people with ADHD and their relatives.

Yours sincerely

Marina Pérez Acosta
President ATIMANA-DAH

ATIMANA-DAH
Avda. La Libertad, Ed. Araucaria 15
Local E 4 – Los Majuelos
Tfno. 922 645 715
E-mail: secretariaatimana@gmail.com



October 18th 2020

Support Letter

Dear Prof. Faraone:

I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children. Methylphenidate is a first line treatment for attention deficit hyperactivity disorder in Kingdom of Saudi Arabia (KSA). Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by the insurance programs that pay for medications. Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment which, in turn, will improve the quality of life of many children with ADHD and the parents that care for them.

Ayman Shawqi Alhazmi, MD

Developmental & behavioral Pediatric consultant
HOD developmental pediatrics, King Saud Medical City.
MOH, Riyadh
KSA



Email: admin@aadpa.com.au
ABN: 85 616 076 049

www.aadpa.com.au

Professor Steven V. Faraone
President
World Federation of ADHD

2 October 2020

Dear Professor Faraone,

I write to provide my strong support for your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children. Methylphenidate is a first line treatment for attention deficit hyperactivity disorder (ADHD) in Australia. ADHD affects around 800,000 people in Australia and is associated with a huge economic and social cost. Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by the insurance programs that pay for medications. Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment which, in turn, will improve the quality of life of many children with ADHD and the parents that care for them.

Yours sincerely,

Professor Mark A. Bellgrove, President

The Australian ADHD Professionals Association (AADPA)

www.aadpa.com.au





Asociación TDAH Bahía de Cádiz

639 066 625

asociaciontdahbahiadecadiz@gmail.com

@asociaciónTDAHcadiz

Professor Stephen Faraone

President World Federation of ADHD Upstate Medical University

12 November 2020

505 Irving Avenue Syracuse . New York

Dear Prof. Faraone:

On behalf of patients in Spain who receive treatment for ADHD I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines. Methylphenidate is a first line treatment for Attention Deficit Hyperactivity Disorder.

Patients with ADHD includes children and adolescents as well as adults. Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 12 years. Children with ADHD have significantly lower ability to focus and sustain attention and score higher on impulsivity and hyperactivity.

Untreated ADHD is not a benign condition and pharmacological interventions such as methylphenidate have wide ranging beneficial effects for patients Spanish wide. For most patients, the impairing symptoms of ADHD persist into adulthood. Because ADHD is a common neurodevelopmental disorder in childhood affecting 5% of children and 2.8% of adults worldwide, limiting access to methylphenidate will have profound repercussions. It also does not consider the many mental and somatic health risks associated with failure to treat ADHD such as accidents, injuries, suicide, and premature death, which have been documented by large population studies or meta-analyses.

This medication has been a lifeline for so many thousands of children allowing them to access their education and very importantly to enjoy a positive family life. It has given them the opportunity to complete their education and move on into further education, university, and employment. All these experiences are crucial to a productive and secure future.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by prescribers. Ultimately it is the patient who then suffers.



TDAH Bahía de Cádiz

Including methylphenidate on the List of Essential Medicines will go a long way to destigmatize a very real treatable condition and it will improve access to this very effective treatment which, in turn, will improve the quality of life of many people with ADHD and their relatives.

Yours sincerely,

Vanesa Clavain

Presidenta Asociación Bahía de Cádiz



October 2, 2020

Stephen V. Faraone, Ph.D.
Distinguished Professor and Vice Chair for Research
Department of Psychiatry, SUNY Upstate Medical University

Dear Dr. Faraone,

I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children. CHADD – the U.S. national organization that supports children and adults with ADHD, their parents, educators and professionals, supports evidence-based science and information regarding ADHD. Results from numerous studies, and direct reports from parents and adults, show that methylphenidate is a first line treatment for attention deficit hyperactivity disorder in the United States. Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by the insurance programs that pay for medications. It is CHADD's position that all individuals with diagnosed ADHD should have access to the full range of safe and effective prescription medications indicated to treat ADHD. In light of the rampant misconceptions about ADHD treatment, the stigma surrounding the disorder, and other external pressures, individuals with ADHD often face significant barriers to accessing prescribed medications. This important medication will improve the quality of life of many children and those that care for them. We respectfully urge the World Health Organization to include methylphenidate on the List of Essential Medicines for Children.

Very truly yours,

Robert Cattoi
Chief Executive Officer
CHADD – Children and Adults with ADHD

Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD)
4221 Forbes Blvd., Suite 270 Lanham, MD 20706; www.chadd.org



DGKJP - Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie,
Psychosomatik und Psychotherapie e.V.
Geschäftsstelle • Reinhardtstraße 27 B • 10117 Berlin

Stephen V. Faraone, PhD
President, World Federation of ADHD
Board Member, American Professional Society of
ADHD and Related Disorders
Distinguished Professor of Psychiatry, SUNY
Upstate Medical University, Syracuse NY, USA
sfaraone@childpsychresearch.org

October 30, 2020

Letter of Support

Dear Prof. Faraone,

I am writing to support your point to include methylphenidate on the World Health Organization's List of Essential Medicines for Children. ADHD is one of the most frequent psychiatric disorders in childhood and adolescence. There is strong evidence for the effectiveness of methylphenidate in the treatment of ADHD. Both the German National Guideline for Diagnostics and Treatment of ADHD (AWMF S3-Leitlinie ADHS bei Kindern, Jugendlichen und Erwachsenen, Registernummer 028-045, <https://www.awmf.org/leitlinien/detail/ll/028-045.html>) and other guidelines (like NICE) recommend MPH as a safe treatment option within child and adolescent psychiatry. There are numerous studies about effects and safety, and there is sound evidence about positive effects to prevent severe negative consequences of ADHD on our patients' later lives (e.g. school performance). In Germany MPH is licensed for the treatment of ADHD. Furthermore, it is an economic choice.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers, as it might impact decisions made by the insurance programs that pay for medications. Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment which, in turn, will improve the quality of life of many children with ADHD and the parents who care for them.

Kind regards

Prof. Michael Kölich
President DGKJP

Präsident

Prof. Dr. med. Michael Kölich
Direktor der Klinik für Psychiatrie, Neurologie,
Psychosomatik und Psychotherapie im Kindes-
und Jugendalter
Universitätsmedizin Rostock

Stellvertretender Präsident und Schatzmeister

Prof. Dr. med. Marcel Romanos
Direktor der Klinik und Poliklinik für Kinder- und
Jugendpsychiatrie, Psychosomatik und
Psychotherapie
Universitätsklinikum Würzburg

Stellvertretender Präsident und Kongresspräsident

Prof. Dr. med. Hans-Henning Flechtner
Direktor der Universitätsklinik für Psychiatrie,
Psychotherapie und Psychosomatische Medizin
des Kindes- und Jugendalters
Otto von Guericke Universität Magdeburg

Schriftführerin

Prof. Dr. med. Dipl.-Theol. Christine M. Freitag
Direktorin der Klinik für Psychiatrie, Psychosomatik
und Psychotherapie des Kindes- und Jugendalters
Universitätsklinikum Frankfurt

Beisitzerin

Prof. Dr. med. Renate Schepker
Regionaldirektorin
ZIP Südwürttemberg, Ravensburg

Beisitzerin

Prof. Dr. rer. nat. Kerstin Konrad
Leitung des Lehr- und Forschungsgebietes Klinische
Neuropsychologie des Kindes- u. Jugendalters
Klinik für Psychiatrie, Psychosomatik und
Psychotherapie des Kindes- und Jugendalters
Universitätsklinikum Aachen

Beisitzer

Prof. Dr. med. Tobias Renner
Direktor der Abteilung Psychiatrie, Psychosomatik
und Psychotherapie im Kindes- und Jugendalter
Universitätsklinikum Tübingen

Ehrenpräsidenten

Prof. em. Dr. med. Dr. phil. Helmut Remschmidt
Marburg

Prof. em. Dr. med. Dr. rer. nat. Martin H. Schmidt
Mannheim

Kooptierte Mitglieder

Dr. med. Martin Jung
Vorsitzender der BAG KJPP

Dr. med. Gundolf Berg
Vorsitzender des BKJPP

Geschäftsstelle

Dr. Mareike Altscher, Dipl.-Soz.
Antje Rößler, Dipl. Betriebswirtin (BA)
Reinhardtstraße 27 B
10117 Berlin
☎ 030 / 28 09 43 86, ☎ 030 / 27 58 15 38
E-mail: geschaeftsstelle@dgkjp.de
Internet: <http://www.dgkjp.de>

Deutsche Apotheker- und Ärztebank

BLZ 300 606 01
Kto-Nr.: 0006788564
IBAN Nr.: DE67 3006 0601 0006 7885 64
BIC (Swift Code): DAAEEDDD

VR 27791 B Amtsgericht Berlin Charlottenburg

Prof. Dr. med. Dominique Eich-Höchli
FMH Psychiatrie und Psychotherapie
Turnerstrasse 26
8006 Zürich

Fon 0041-43 243 35 35

Zürich, October 30th, 2020

Dear Prof. Faraone

I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children.

Methylphenidate is a first line treatment for attention deficit hyperactivity disorder in **Switzerland**.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by the insurance programs that pay for medications. Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment which, in turn, will improve the quality of life of many children with ADHD and the parents that care for them.



Dominique Eich-Höchli, MD, Prof.
Co-President of the Swiss Society for ADHD

Prof. Dr. med. Dominique Eich
FMH Psychiatrie & Psychotherapie
Turnerstrasse 26
CH-8006 Zürich
W 133501



Schweizerische Fachgesellschaft ADHS
Société suisse pour le TDAH
Società svizzera per l'ADHD
Swiss Society for ADHD

Cagliari, Madrid, October 27th, 2020

Prof. Stephen V. Faraone, PhD
President, World Federation of ADHD
Distinguished Professor of Psychiatry, SUNY
Upstate Medical University, Syracuse NY, USA

Dear Prof. Faraone,


I am writing to strongly support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children.

Methylphenidate is a first line treatment for attention deficit hyperactivity disorder in Italy, Spain and the other 10 countries represented at the European Network of Child Adolescent Neuropsychopharmacology (at the European College of Neuropsychopharmacology-ECNP).

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of, prescribers, the compliance of parents and young children and impacts decisions made by the insurance programs that pay for medications.

Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment which, in turn, will improve the quality of life of many children and adolescents with ADHD and the parents that care for them.

Kind regards



Alessandro Zuddas, MD
Chair of ECNP Network of Child Adolescent Neuropsychopharmacology
Professor of Child Neuropsychiatry
Dept. Biomedical Sciences, Sect. Neuroscience & Clinical Pharmacology
University of Cagliari, Cagliari, Italy



Carmen Moreno, MD, PhD
Co-Chair of ECNP Network of Child Adolescent Neuropsychopharmacology
Child and Adolescent Psychiatry Department
Institute of Psychiatry and Mental Health
Hospital General Universitario Gregorio Marañón, Madrid, Spain

SECRETARIAT
ECNP OFFICE
T: +31 88 75 69 555
F: +31 88 75 59 900
E. secretariat@ecnp.eu

POSTAL ADDRESS
PO BOX 85410
3508 AK Utrecht
The Netherlands
www.ecnp.eu

VISITING ADDRESS
Bolognalaan 28
3584CJ Utrecht
The Netherlands



Athens, 12/11/2020

The ESCAP Board:

President:

Pr Dimitris Anagnostopoulos

Email: danagnostopoulos@escap.eu or dimitris1952@gmail.com

Past President:

Pr Stephan Eliez

Email: stephan.eliez@pole-autisme.ch

Treasurer:

Pr Jean-Philippe Raynaud

Email: raynaud.jph@chu-toulouse.fr

Board Secretary:

Dr Maeve B. Doyle

Email: doyle.maeve334@gmail.com

Members:

Dr Anne Marie Råberg Christensen - Denmark

Pr Joerg Fegert - Germany

Dr Konstantinos Kotsis - Greece

Pr Manon Hillegers – The Netherlands

Dr Milica Pejovic-Milovencevic - Serbia

Pr Andreas Karwautz – Austria

Dr Eniko Kiss – Hungary

Pr Johannes Hebebrand, *Editor-in-chief of the ECAP*

Dear Prof. Faraone,

On behalf of the European Society for Child and Adolescent Psychiatry (ESCAP), I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children.

Methylphenidate is a first-choice pharmacological treatment for children suffering with ADHD. The safety and efficacy of methylphenidate has been strongly demonstrated based on extended research and clinical evidences. Like in other disorders e.g. hypertension or diabetes everyone should have access to a medication that has shown effectiveness and is recommended in all international and European guidelines. Including methylphenidate on the List of Essential Medicines will improve access to this effective treatment which, in turn, will improve the quality of life of many children with ADHD and the parents that care for them.

Wishing that your application will be successful.

Kind regards,

Dimitris Anagnostopoulos

Dimitris C. Anagnostopoulos MD, PhD
Professor of Child and Adolescent Psychiatry,
National & Kapodistrian University of Athens
President, European Society for Child and Adolescent Psychiatry
danagnost@med.uoa.gr, danagnostopoulos@escap.eu
Mobile: 00306973303375, FT, WhatsApp, Viber



National and Kapodistrian
UNIVERSITY OF ATHENS

European Society for Child and Adolescent Psychiatry – ESCAP
ESCAP Online
E-mail: info@escap.eu



**Federación Asociaciones TDAH
CASTILLA Y LEÓN**

Professor Stephen Faraone
President World Federation of ADHD Upstate Medical University
505 Irving Avenue Syracuse
New York

12 November 2020

Dear Prof. Faraone:

On behalf of patients in Castilla y León who receive treatment for ADHD I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines. Methylphenidate is a first line treatment for Attention Deficit Hyperactivity Disorder.

Patients with ADHD includes children and adolescents as well as adults. Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 12 years. Children with ADHD have significantly lower ability to focus and sustain attention and score higher on impulsivity and hyperactivity.

Untreated ADHD is not a benign condition and pharmacological interventions such as methylphenidate have wide ranging beneficial effects for patients Spanish wide. For most patients, the impairing symptoms of ADHD persist into adulthood. Because ADHD is a common neurodevelopmental disorder in childhood affecting 5% of children and 2.8% of adults worldwide, limiting access to methylphenidate will have profound repercussions. It also does not consider the many mental and somatic health risks associated with failure to treat ADHD such as accidents, injuries, suicide, and premature death, which have been documented by large population studies or meta-analyses.

This medication has been a lifeline for so many thousands of children allowing them to access their education and very importantly to enjoy a positive family life. It has given them the opportunity to complete their education and move on into further education, university, and employment. All these experiences are crucial to a productive and secure future.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by prescribers. Ultimately it is the patient who then suffers.

Including methylphenidate on the List of Essential Medicines will go a long way to destigmatize a very real treatable condition and it will improve access to this very effective treatment which, in turn, will improve the quality of life of many people with ADHD and their relatives.

Yours sincerely

Mª Cristina E. Peña Ruiz,
President FACYL-TDAH



Professor Stephen Faraone
President World Federation of ADHD Upstate Medical University
505 Irving Avenue Syracuse
New York

12 November 2020

Dear Prof. Faraone:

On behalf of patients in Spain who receive treatment for ADHD I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines. Methylphenidate is a first line treatment for Attention Deficit Hyperactivity Disorder.

Patients with ADHD includes children and adolescents as well as adults. Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 12 years. Children with ADHD have significantly lower ability to focus and sustain attention and score higher on impulsivity and hyperactivity.

Untreated ADHD is not a benign condition and pharmacological interventions such as methylphenidate have wide ranging beneficial effects for patients Spanish wide. For most patients, the impairing symptoms of ADHD persist into adulthood. Because ADHD is a common neurodevelopmental disorder in childhood affecting 5% of children and 2.8% of adults worldwide, limiting access to methylphenidate will have profound repercussions. It also does not consider the many mental and somatic health risks associated with failure to treat ADHD such as accidents, injuries, suicide, and premature death, which have been documented by large population studies or meta-analyses.

This medication has been a lifeline for so many thousands of children allowing them to access their education and very importantly to enjoy a positive family life. It has given them the opportunity to complete their education and move on into further education, university, and employment. All these experiences are crucial to a productive and secure future.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by prescribers. Ultimately it is the patient who then suffers.

Including methylphenidate on the List of Essential Medicines will go a long way to destigmatize a very real treatable condition and it will improve access to this very effective treatment which, in turn, will improve the quality of life of many people with ADHD and their relatives.

Yours sincerely
Firmado por
34100719E MAITE
URKIZU (R:
G30787261) el día
Maite Urkizu Morán 12/11/2020 con un
President FEAADAH certificado emitido
por AC
Representación

Professor Stephen Faraone

President World Federation of ADHD Upstate Medical University

12 November 2020

505 Irving Avenue Syracuse

New York

Dear Prof. Faraone:

On behalf of patients in Spain who receive treatment for ADHD I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines. Methylphenidate is a first line treatment for Attention Deficit Hyperactivity Disorder.

Patients with ADHD includes children and adolescents as well as adults. Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 12 years. Children with ADHD have significantly lower ability to focus and sustain attention and score higher on impulsivity and hyperactivity.

Untreated ADHD is not a benign condition and pharmacological interventions such as methylphenidate have wide ranging beneficial effects for patients Spanish wide. For most patients, the impairing symptoms of ADHD persist into adulthood. Because ADHD is a common neurodevelopmental disorder in childhood affecting 5% of children and 2.8% of adults worldwide, limiting access to methylphenidate will have profound repercussions. It also does not consider the many mental and somatic health risks associated with failure to treat ADHD such as accidents, injuries, suicide, and premature death, which have been documented by large population studies or meta-analyses.

This medication has been a lifeline for so many thousands of children allowing them to access their education and very importantly to enjoy a positive family life. It has given them the opportunity to complete their education and move on into further education, university, and employment. All these experiences are crucial to a productive and secure future.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by prescribers. Ultimately it is the patient who then suffers.

Including methylphenidate on the List of Essential Medicines will go a long way to destigmatize a very real treatable condition and it will improve access to this very effective treatment which, in turn, will improve the quality of life of many people with ADHD and their relatives.

Yours sincerely



Montserrat Álvarez Rodríguez

President FEGADAH

FEDERACIÓN GALEGA DE ASOCIACIÓN DE DÉFICIT DE ATENCIÓN E HIPERACTIVIDADE
ANIHDA (Vigo) - ANIHDA CORUÑA (A Coruña) - ADAHPO (Pontevedra-Vilagarcía de Arousa - Ourense) - ACNH
(Santiago) - BULEBULE (Lugo)R. / Rosalía de Castro, 36, Baixo. 36001 (Pontevedra) -Telfs.: 655146134
CIF: G94128469. Email: presidencia@fegadah.org



Panda SA

The Paediatric Neurology and Development Association of Southern Africa

5th October 2020

Dear Prof. Faraone

Re: Inclusion of methylphenidate on WHO List of Essential Medicines for Children

I am writing to you on behalf of PANDA SA (Paediatric Neurology and Development Association of Southern Africa) as we strongly believe that methylphenidate needs to be included on the World Health Organization's List of Essential Medicines for Children.

Therefore, I would like to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children. Methylphenidate is a first line treatment for attention deficit hyperactivity disorder in South Africa both in the public and private sectors. In the public sector there is no access to other treatments for ADHD.

We feel that excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by the insurance programs that pay for medications. Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment which, in turn, will improve the quality of life of many children with ADHD and their caregivers.

Kind regards

Prof Gail Scher
Paediatric Neurologist
Chairperson PANDA SA (Paediatric Neurology and Development Association of Southern Africa)

Department of Paediatrics and Child Health, University of the Witwatersrand
P O Box 1804
Houghton
Johannesburg
South Africa
2041



October 1, 2020

To: Stephen V. Faraone, PhD
President, World Federation of ADHD
Board Member, American Professional Society of ADHD and Related Disorders
Distinguished Professor of Psychiatry, SUNY Upstate Medical University, Syracuse NY, USA

RE: WHO List of Essential Medicines for Children

Dear Prof. Faraone,

I am writing to support your application for including methylphenidate on the World Health Organization's (WHO) List of Essential Medicines for Children.

The Canadian ADHD Practice Guidelines, 4.1 Edition (2020) includes methylphenidate as a first line treatment for attention deficit hyperactivity disorder in Canada. The decision of the WHO to exclude methylphenidate from its List of Essential Medicines is contrary to Canadian expert clinical consensus. Moreover, it undermines the confidence of prescribers and impacts decisions made by the insurance programs that pay for medications.

Medications are part of an integrated and multimodal treatment plan for ADHD. Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment. Research has shown that early treatment of ADHD is a strong preventive measure in the field of mental health. Furthermore, it will improve the quality of life of many children with ADHD and the parents that care for them.

Yours faithfully,

Martin Gignac MD FRCPC
Chair, CADDRA Board of Directors
CADDRA – Canadian ADHD Resource Alliance
Associate Professor, McGill University, Montreal, Qc, Canada



Dear Prof. Faraone:

I am writing on behalf of the Centre for ADHD Awareness Canada (CADDAC), a national charity dedicated to improving the lives of families and individuals with ADHD, to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children. While we consider Methylphenidate a second line treatment for attention deficit hyperactivity disorder in Canada, due to its briefer duration of action, we do consider it to be an essential medication for the treatment of ADHD world-wide. Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by governments and insurance programs that pay for medications. Including methylphenidate on the List of Essential Medicines will improve access to this treatment which, in turn, will improve the quality of life of many children with ADHD and their families.

Heidi Bernhardt
Founder and President
Centre for ADHD Awareness Canada
366 Adelaide St E, Suite 221 Toronto,
ON Canada M5A 3X9



Dear Professor Faraone,

My name is Iane Kestelman; I am the president of the Brazilian Association for Attention Deficit Disorder (ABDA) - the only and largest Non-Profit Organization, an entity representing the rights of people with ADHD in Brazil.

The reason for this email is to affirm my support for the World Health Organization in order to recognize the list of essential medications for the treatment of children with ADHD and the use of methylphenidate.

In my country the most used medication for the treatment of children with ADHD is methylphenidate, due to its low cost and also because the Brazilian Health Agency (ANVISA) only makes medications based on methylphenidate and Lisdexamfetamine available for ADHD.

The exclusion of Ritalin from the list of essential medications is certain to have a negative impact on an absurd number of people and will cause problems of a social nature by interrupting important health policies that are carried out with children with ADHD in Brazil.

On behalf of the association, I reaffirm the need for methylphenidate in order to improve the quality, treatment and social inclusion of all children with ADHD in my country and, on behalf of them, I request the inclusion of the medication mentioned in the list.

Yours sincerely,

Iane Kestelman



Iane Kestelman
Presidente
Fone: 55(21) 3217.75
www.tdah.org.br

www.tdah.org.br



10-14-20

Dear Prof. Faraone:

I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children.

Methylphenidate is the sole first line treatment for Attention Deficit Hyperactivity Disorder (ADHD) in Israel.

Its exclusion from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by the insurance programs that pay for medications.

Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment which, in turn, will improve the quality of life of many children with ADHD and the parents that care for them.

Professor Iris Manor

Senior Child and Adolescent psychiatrist

Director of the ADHD clinic, Geha MHC, Petah-Tikva, Israel

Associate professor, Sackler school of medicine, Tel Aviv University, Israel

Chair of the Israeli Society of ADHD



October 15, 2020

Dear Prof. Faraone:

I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children.

Methylphenidate is a first line treatment for attention deficit hyperactivity disorder in México, where there is more than a two million and a half of children with these disorder.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by the programs that pay for medications.

Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment which, in turn, will improve the quality of life of many children with ADHD and the parents that care for them.

The negative impacts on children who do not receive Methylphenidate substantially affect them, their families and society in general, for which we strongly support their inclusion.



Dr. Juan Carlos Pérez Castro Vázquez

Director General



Dear Professor Faraone:

The Catalan Federation of Associations of Relatives and People Affected by ADHD (FCAFA-TDAH) supports your request to include methylphenidate in the list of essential medicines for children of the World Health Organization. In Spain, and in Catalonia specifically, methylphenidate is a first-line treatment for attention deficit hyperactivity disorder prescribed by practically the majority of mental health professionals, and is trusted by thousands of families for treatment of this disorder for its innumerable advantages. Excluding methylphenidate from the list of essential medicines would cause thousands of children in Spain to abandon treatment by affecting this decision to the public health system and a very important economic decline in Spanish families. The inclusion of methylphenidate on the essential drug list will improve access to this highly effective treatment and, in turn, improve the quality of life for many children with ADHD and the parents who care for them.

Greetings,

A handwritten signature in black ink, appearing to read 'Juan Pérez Caro', with a stylized flourish at the end.

Juan Pérez Caro
President of the Catalan
Federation of Relatives and
People Affected by ADHD
(FCAFA-TDAH).

Onderwerp

The Hague, 9 oktober 2020

Dear Prof. Faraone,

I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children.

Methylphenidate is a first line treatment for attention deficit hyperactivity disorder in the Netherlands. Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by the insurance programs that pay for medications. Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment which, in turn, will improve the quality of life of many children with ADHD and the parents that care for them.



Prof. Dr. J.J.S. Kooij, psychiatrist

Amsterdam University Medical Center/VUmc, Amsterdam, the Netherlands
& PsyQ, psychomedical Programs, the Hague, the Netherlands



Fundación Cultural
Federico Hoth A.C.

Proyectodah®

October 15, 2020

Dear Prof. Faraone:

I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children.

Methylphenidate is a first line treatment for attention deficit hyperactivity disorder in México.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by the programs that pay for medications.

Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment which, in turn, will improve the quality of life of many children with ADHD and the parents that care for them.

Mtra. María Elena Frade Rubio

President and Founder



Torresco No. 6, Col. Santa Catarina, Deleg. Coyoacán,
C.P. 04010, México, D.F.
Tels: (55) 5658 7122 (55) 5339 5065 (55) 5339 5936
RFC: FCF000926EEA
www.cerebrofeliz.org



Encuentro

TDAH

LIGA LATINOAMERICANA LILAPETDAH 2022

Santo Domingo, República Dominicana

Junta Directiva

Dra. Zuleika Morillo

Presidenta

Dr. Gastón Schmidt

Vicepresidente

Dr. Javier Adi

Secretario General

Dra. Laura Viola

Comité Científico

Dra. Andrea Abadi

Comité Manejo

Medios y

Divulgación

Subject: Written Support from LILAPETDAH

Dear Prof. Faraone,

On behalf of all countries of Latin America that form part of the Latin American League for the study and research of ADHD, we join to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children. Methylphenidate is a first-line treatment for attention deficit hyperactivity disorder in Latin America. Maintaining methylphenidate included on the List of Essential Medicines will improve the quality of life of many children living with ADHD and the parents that care for them.

Zuleika Morillo de Nieto, MD
President of the Latinamerican Federation and Association of Child & Adolescent Psychiatrists and related professions, FLAPIA.
President of the Latinamerican League for the study of ADHD, Lilapetdah.
Chief Manager of the Mental Health Department Robert Reid Hospital, Santo Dgo.
Coordinator of the Child & Adolescent Residency program in Robert Reid Hospital.
Child & Adolescent Psychiatrist professor of the Pediatric and general Psychiatry Residency programs.
Professor in the Psychology school of the Catholic University of Santo Domingo and the Iberoamericano University of Santo Domingo.
Chair of laedp. International Chapter Association of Eating Disorders Professionals
Clinic Director of medical service CPE/Renovatus, special program for eating disorders, Santo Domingo.



Asociación TDA- H PALENCIA
Entidad sin ánimo de lucro, G-34243832

Es miembro de:



Federación Asociaciones TDAH
CASTILLA Y LEÓN

Professor Stephen Faraone

President World Federation of ADHD Upstate Medical University

12 November 2020

505 Irving Avenue Syracuse

New York

Dear Prof. Faraone:

On behalf of patients in Spain who receive treatment for ADHD I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines. Methylphenidate is a first line treatment for Attention Deficit Hyperactivity Disorder.

Patients with ADHD includes children and adolescents as well as adults. Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 12 years. Children with ADHD have significantly lower ability to focus and sustain attention and score higher on impulsivity and hyperactivity.

Untreated ADHD is not a benign condition and pharmacological interventions such as methylphenidate have wide ranging beneficial effects for patients Spanish wide. For most patients, the impairing symptoms of ADHD persist into adulthood. Because ADHD is a common neurodevelopmental disorder in childhood affecting 5% of children and 2.8% of adults worldwide, limiting access to methylphenidate will have profound repercussions. It also does not consider the many mental and somatic health risks associated with failure to treat ADHD such as accidents, injuries, suicide, and premature death, which have been documented by large population studies or meta-analyses.

This medication has been a lifeline for so many thousands of children allowing them to access their education and very importantly to enjoy a positive family life. It has given them the opportunity to complete their education and move on into further education, university, and employment. All these experiences are crucial to a productive and secure future.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by prescribers. Ultimately it is the patient who then suffers.

Including methylphenidate on the List of Essential Medicines will go a long way to destigmatize a very real treatable condition and it will improve access to this very effective treatment which, in turn, will improve the quality of life of many people with ADHD and their relatives.

Yours sincerely

José Antonio Hoyos Álvarez
President TDA-H PALENCIA

Firmado por 12730853P JOSE ANTONIO HOYOS (R:
G34243832) el día 12/11/2020 con un
certificado emitido por AC Representación

- ✓ Inscrita en el Registro de Asociaciones de la Delegación Territorial de la Junta de Castilla y León en Palencia con el nº 0002150 de la sección PRIMERA.
- ✓ Inscrita en el Registro Municipal de Asociaciones de Palencia con el nº 430.
- ✓ Inscrita en el Registro de Entidades, Servicios y Centros de Carácter Social de la Gerencia de Servicios sociales de Castilla y León con el nº de entidad 34.0397E, sección Entidades página 397, folio 1. Inscrito con el nº 34.0612S, sección Servicios y Centros, página 612, folio 1 el Programa de actividades destinados a menores en riesgo y personas con discapacidad afectados por TDAH.
- ✓ Acreditado e Inscrito el Servicio de Promoción de la Autonomía Personal, Estimulación Cognitiva con el nº 340866 en el Registro de Entidades, Servicios y Centros de la Gerencia de Servicios sociales de Castilla y León
- ✓ Inscrita en Registro Regional de Entidades del Voluntariado de Castilla y León con el nº A-0355.

☎: 979 110 330 / 663 803 898 🌐: www.tdah-palencia.es @: info@tdah-palencia.es



Professor Stephen Faraone

President World Federation of ADHD Upstate Medical University

12 November 2020

505 Irving Avenue Syracuse

New York

Dear Prof. Faraone:

On behalf of patients in Spain who receive treatment for ADHD I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines. Methylphenidate is a first line treatment for Attention Deficit Hyperactivity Disorder.

Patients with ADHD includes children and adolescents as well as adults. Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 12 years. Children with ADHD have significantly lower ability to focus and sustain attention and score higher on impulsivity and hyperactivity.

Untreated ADHD is not a benign condition and pharmacological interventions such as methylphenidate have wide ranging beneficial effects for patients Spanish wide. For most patients, the impairing symptoms of ADHD persist into adulthood. Because ADHD is a common neurodevelopmental disorder in childhood affecting 5% of children and 2.8% of adults worldwide, limiting access to methylphenidate will have profound repercussions. It also does not consider the many mental and somatic health risks associated with failure to treat ADHD such as accidents, injuries, suicide, and premature death, which have been documented by large population studies or meta-analyses.

This medication has been a lifeline for so many thousands of children allowing them to access their education and very importantly to enjoy a positive family life. It has given them the opportunity to complete their education and move on into further education, university, and employment. All these experiences are crucial to a productive and secure future.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by prescribers. Ultimately it is the patient who then suffers.

Including methylphenidate on the List of Essential Medicines will go a long way to destigmatize a very real treatable condition and it will improve access to this very effective treatment which, in turn, will improve the quality of life of many people with ADHD and their relatives.

Yours sincerely

Maria Fe Rico Nieto

President of TDAH AXARQUIA Association

Member of FEAADAH, FAHYDA AND ADHD EUROPE

ASOCIACION TDAH AXARQUIA, G93045607, VÉLEZ-MÁLAGA
INSCRITA EN EL REGISTRO DE ASOCIACIONES DE ANDALUCÍA, UNIDAD REGISTRAL DE
MÁLAGA, Nº 8811 DE LA SECCIÓN 1ª. TLF. 650358939 tdahaxarquia@gmail.com

Dear Prof. Faraone:

I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children. Methylphenidate is a first line treatment for attention deficit hyperactivity disorder in NAME OF COUNTRY. Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by the insurance programs that pay for medications. Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment which, in turn, will improve the quality of life of many children with ADHD and the parents that care for them.



Yi Zheng, MD. President,
Chinese Society of Child and Adolescent Psychiatry;
Asian Federation of ADHD;

Add: Beijing Anding Hospital, Capital Medical University
Beijing, 100088 P.R. China
E-mail: yizheng@ccmu.edu.cn

APSARD



The American Professional Society
of ADHD and Related Disorders

October 2, 2020

Dear Dr. Faraone,

As President of the American Professional Society of ADHD and Related Disorders (APSARD), I am writing regarding your application to include methylphenidate on the list of Essential Medicines for Children by the World Health Organization (WHO). I, and my organization, strongly support the addition of methylphenidate, which is an important first line treatment for attention-deficit/hyperactivity disorder in the United States of America and also world-wide. Excluding methylphenidate from the list is not a fair representation of the importance of this medication in treating children and adolescents. Moreover, excluding it from the list could weaken confidence in this intervention for prescribers and insurance companies. It is important to emphasize that methylphenidate has a very large effect for youth with ADHD – one of the largest in psychiatry and, in fact, all of medicine. It has a major impact on the quality of life for children with ADHD and their parents. The importance of this information cannot be overstated; ADHD is a highly prevalent and impairing disorder in children, and methylphenidate is a highly effective treatment for this condition. Including methylphenidate on the World Health Organization's List of Essential Medicines for Children will recognize the importance of this medication in the treatment of millions of children world-wide. This is a vitally important issue, and I hope the WHO will give it serious consideration.

Sincerely,

A handwritten signature in black ink, appearing to read "Jeff Newcorn MD", with a stylized flourish at the end.

Jeffrey H. Newcorn, MD

President, American Professional Society of ADHD and Related disorders (APSARD)

To whom it may concern

Prof. Dr. Dr. T. Banaschewski
Chairman

Central Institute of Mental Health
Postbox: 12 21 20
D-68072 Mannheim
Tobias.Banaschewski@zi-mannheim.de
T: +49 / (0)621 / 1703 – 4502
F: +49 / (0)621 / 1703 – 4505

Prof. Dr. J.K. Buitelaar
Secretary and Treasurer
Stichting Eunethydis Foundation
Paijensweg 6
NL-6523 MC Nijmegen
Jan.Buitelaar@radboudumc.nl

Mannheim, 10/27/2020

Subject: Support application for including methylphenidate

Dear Prof. Faraone,

we are writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children. Methylphenidate is a first line treatment for attention deficit hyperactivity disorder in Europe. Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by the insurance programs that pay for medications.

Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment which, in turn, will improve the quality of life of many children with ADHD and the parents that care for them.

Yours sincerely,



Professor Tobias Banaschewski
Chairman of the Eunethydis Network



Prof. Dr. J.K. Buitelaar
Secretary and Treasurer

Tobias Banaschewski, MD, PhD,
Professor of Child and Adolescent Psychiatry

Chairman of the Eunethydis Network

1/1



Professor Stephen Faraone

President World Federation of ADHD Upstate Medical University

505 Irving Avenue Syracuse

New York

10 November 2020

Dear Prof. Faraone:

On behalf of patients in Europe who receive treatment for ADHD I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines. Methylphenidate is a first line treatment for Attention Deficit Hyperactivity Disorder in all European countries.

Patients with ADHD includes children and adolescents as well as adults. Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 12 years. Children with ADHD have significantly lower ability to focus and sustain attention and score higher on impulsivity and hyperactivity.

Untreated ADHD is not a benign condition and pharmacological interventions such as methylphenidate have wide ranging beneficial effects for patients European wide. For most patients, the impairing symptoms of ADHD persist into adulthood. Because ADHD is a common neurodevelopmental disorder in childhood affecting 5% of children and 2.8% of adults worldwide, limiting access to methylphenidate will have profound repercussions. It also does not consider the many mental and somatic health risks associated with failure to treat ADHD such as accidents, injuries, suicide, and premature death, which have been documented by large population studies or meta-analyses.

This medication has been a lifeline for so many thousands of children allowing them to access their education and very importantly to enjoy a positive family life. It has given them the opportunity to complete their education and move on into further education, university, and employment. All these experiences are crucial to a productive and secure future.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by prescribers. Ultimately it is the patient who then suffers.

Including methylphenidate on the List of Essential Medicines will go a long way to destigmatize a very real treatable condition and it will improve access to this very effective treatment which, in turn, will improve the quality of life of many people with ADHD and their relatives.

Yours sincerely

Dr. Myriam Bea

President ADHD Europe

ADHD Europe aisbl, Rue Washington straat 40/5, Brussels, Belgium, 1050

Registered International Non-Profit Organization in Belgium: 0810.982.059

www.adhdeurope.eu

Cosigned by National organisations



K. Kilbride

Ken Kilbride, CEO, ADHD Ireland



Elin H. Hinriksdóttir

Elin Hoe Hinriksdóttir M.Ed.

Chair, ADHD association Iceland.

Board member of The Icelandic Disability Alliance



Christine Jarvis

ADHD Solutions CIC

Director/CEO ADHD Solutions CIC



ADHD Europe aisbl, Rue Washington straat 40/5, Brussels, Belgium, 1050
Registered International Non-Profit Organization in Belgium: 0810.982.059
www.adhdeurope.eu



Dr. Dominique Bertholdt

Treffpunkt ADHS.Asbl

Luxemburg

National President

Associazione Italiana Famiglie ADHD Organizzazione di Volontariato

National Vice President

Associazione Italiana Famiglie ADHD Organizzazione di Volontariato



Beverley Sinton
President of ADHD, ASC & LD Belgium
European Brain Ambassador

ADHD Europe asbl, Rue Washington straat 40/5, Brussels, Belgium, 1050
Registered International Non-Profit Organization in Belgium: 0810.982.059
www.adhdeurope.eu



Hartmut Gartzke
Vorsitzender
ADHS Deutschland e. V.



ADHD
- foreningen

Trish Nymark Vice President
Danish ADHD Organization



Christine GETIN
Présidente
HyperSupers - TDAH France



ASOCIACIÓN DE AFECTADOS POR TDAH DE MADRID.

C/ Molina de Segura, 33 28030 Madrid

91 3560207

657371999 - 691530347

info@anshda.org

www.anshda.org

12 November 2020.

Professor Stephen Faraone
President World Federation of ADHD Upstate Medical University
505 Irving Avenue Syracuse
New York

Dear Prof. Faraone:

On behalf of patients in Spain who receive treatment for ADHD I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines. Methylphenidate is a first line treatment for Attention Deficit Hyperactivity Disorder.

Patients with ADHD includes children and adolescents as well as adults. Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 12 years. Children with ADHD have significantly lower ability to focus and sustain attention and score higher on impulsivity and hyperactivity.

Untreated ADHD is not a benign condition and pharmacological interventions such as methylphenidate have wide ranging beneficial effects for patients Spanish wide. For most patients, the impairing symptoms of ADHD persist into adulthood. Because ADHD is a common neurodevelopmental disorder in childhood affecting 5% of children and 2.8% of adults worldwide, limiting access to methylphenidate will have profound repercussions. It also does not consider the many mental and somatic health risks associated with failure to treat ADHD such as accidents, injuries, suicide, and premature death, which have been documented by large population studies or meta-analyses.

This medication has been a lifeline for so many thousands of children allowing them to access their education and very importantly to enjoy a positive family life. It has given them the opportunity to complete their education and move on into further education, university, and employment. All these experiences are crucial to a productive and secure future.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by prescribers. Ultimately it is the patient who then suffers.

Including methylphenidate on the List of Essential Medicines will go a long way to destigmatize a very real treatable condition and it will improve access to this very effective treatment which, in turn, will improve the quality of life of many people with ADHD and their relatives.

Yours sincerely,
Teresa Moras Cítores
President ANSHDA.



 Anshda Tda-h Madrid
 @TDAHmadrid  @TDAHmadrid



Federación Andaluza de Asociaciones de Ayuda al TDAH

T 693 728 555

fahyda.org@gmail.com

<http://fahyda.blogspot.com/>

Professor Stephen Faraone
President World Federation of ADHD Upstate Medical University
505 Irving Avenue Syracuse
New York

12 November 2020

Dear Prof. Faraone:

On behalf of patients in Spain who receive treatment for ADHD I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines. Methylphenidate is a first line treatment for Attention Deficit Hyperactivity Disorder.

Patients with ADHD includes children and adolescents as well as adults. Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 12 years. Children with ADHD have significantly lower ability to focus and sustain attention and score higher on impulsivity and hyperactivity.

Untreated ADHD is not a benign condition and pharmacological interventions such as methylphenidate have wide ranging beneficial effects for patients Spanish wide. For most patients, the impairing symptoms of ADHD persist into adulthood. Because ADHD is a common neurodevelopmental disorder in childhood affecting 5% of children and 2.8% of adults worldwide, limiting access to methylphenidate will have profound repercussions. It also does not consider the many mental and somatic health risks associated with failure to treat ADHD such as accidents, injuries, suicide, and premature death, which have been documented by large population studies or meta-analyses.

This medication has been a lifeline for so many thousands of children allowing them to access their education and very importantly to enjoy a positive family life. It has given them the opportunity to complete their education and move on into further education, university, and employment. All these experiences are crucial to a productive and secure future.

Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by prescribers. Ultimately it is the patient who then suffers.

Including methylphenidate on the List of Essential Medicines will go a long way to destigmatize a very real treatable condition and it will improve access to this very effective treatment which, in turn, will improve the quality of life of many people with ADHD and their relatives.

Yours sincerely



FAHYDA
NIF G-91720219
Federación Andaluza de Asociaciones de Ayuda
al Trastorno Hiperactivo y Déficit de Atención
Telf 693 728 555

Juan Ángel Quirós Cantos
President FAHYDA



Federación Andaluza de Asociaciones de Ayuda al TDAH

T 693 728 555

fahyda.org@gmail.com

<http://fahyda.blogspot.com/>

From: "宮島祐." <miyajima-t@tokyo-kasei.ac.jp>
Sent: Wednesday, November 18, 2020 7:38 AM
To: Steve Faraone <sfaraone@childpsychresearch.org>
Subject: Re: WHO application

Dear Prof. Faraone:

I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children. Methylphenidate is a first line treatment for attention deficit hyperactivity disorder in Japan. Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by the insurance programs that pay for medications. Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment which, in turn, will improve the quality of life of many children with ADHD and the parents that care for them.

Tasuku Miyajima, M.D. Ph.D
Professor & Chairman

Department of Education for Childcare, Tokyo Kasei University

Miyajima-t@tokyo-kasei.ac.jp

2-15-1 Inariyama, Sayama, Saitama, 350-1398, Japan
TEL: +81-(0)4-2952-1621, FAX: +81-(0)4-2955-6944
President of Japanese Society of ADHD



11-11-2020

Dear Prof. Faraone:

I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children. Methylphenidate is a first line treatment for attention deficit hyperactivity disorder in the Netherlands. Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and impacts decisions made by the insurance programs that pay for medications. Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment which, in turn, will improve the quality of life of many children with ADHD and the parents that care for them.

Rob Rodrigues Pereira, pediatrician

Chairman Impuls en Woortblind

Organisation for individuals with AD(H)D and dyslexia/dyscalculia

Postbus 1058, 3860 BB Nijkerk, the Netherlands

Ref No.....
In replying the above
Number and date of this
letter should be quoted



MINISTRY OF HEALTH
RICHMOND HILL INSTITUTIONS
C/O MT. GAY HOSPITAL
MT. GAY, ST. GEORGE'S
GRENADA W.I.

October 23, 2020

The Secretary of the 22nd Expert Committee on the Selection and Use of Essential Medicines
Medicine Access and Rational Use (MAR)
Department of Essential Medicines and Health Products (EMP)
World Health Organization
20 Avenue Appia
CH-1211 Geneva 27
Switzerland

Dear Secretariat,

I am writing to on behalf of the Mt. Gay Mental Hospital in support of the application being made by Dr. Craig Katz and his colleagues at Mount Sinai School of Medicine to have Methylphenidate added to the List of Essential Medications. We have collaborated with them for over 3 years on meeting mental health needs in our own country and see their decision to make this application on behalf of people around the world as showing great initiative and wisdom. We have much experience with Methylphenidate.

We believe that at least one central nervous system stimulant should be considered an essential part of any formulary, and our experience definitely supports that it should be Methylphenidate. I would like to make a special appeal that it be included in its immediate-release formulations.

Respectfully,

.....
Dr. Evelyn Spencer MD
House Officer
Mt. Gay Psychiatric Hospital

Tel: 1 (473) 440 – 3154/3272 Fax: 1 (473) 435 – 4160 mtgayhsp@health.gov.gd

Ref No.....
In replying the above
Number and date of this
letter should be quoted



MINISTRY OF HEALTH
RICHMOND HILL INSTITUTIONS
C/O MT. GAY HOSPITAL
MT. GAY, ST. GEORGE'S
GRENADA W.I.

October 23, 2020

The Secretary of the 22nd Expert Committee on the Selection and Use of Essential Medicines
Medicine Access and Rational Use (MAR)
Department of Essential Medicines and Health Products (EMP)
World Health Organization
20 Avenue Appia
CH-1211 Geneva 27
Switzerland

Dear Secretariat,

I am writing to on behalf of the Mt. Gay Mental Hospital in support of the application being made by Dr. Craig Katz and his colleagues at Mount Sinai School of Medicine to have Methylphenidate added to the List of Essential Medications. We have collaborated with them for over 3 years on meeting mental health needs in our own country and see their decision to make this application on behalf of people around the world as showing great initiative and wisdom. We have much experience with Methylphenidate.

We believe that at least one central nervous system stimulant should be considered an essential part of any formulary, and our experience definitely supports that it should be Methylphenidate. I would like to make a special appeal that it be included in its immediate-release formulations.

Respectfully,

A handwritten signature in blue ink, appearing to read 'Dr. Arelys'.

Dr. Arelys Francia Vasconcelos
Consultant Psychiatrist
Mt. Gay Psychiatric Hospital

Tel: 1 (473) 440 – 3154/3272 Fax: 1 (473) 435 – 4160 mtgayhsp@health.gov.gd

Ref No.....
In replying the above
Number and date of this
letter should be quoted



MINISTRY OF HEALTH
RICHMOND HILL INSTITUTIONS
C/O MT. GAY HOSPITAL
MT. GAY, ST. GEORGE'S
GRENADA W.I.

October 23, 2020

The Secretary of the 22nd Expert Committee on the Selection and Use of Essential Medicines
Medicine Access and Rational Use (MAR)
Department of Essential Medicines and Health Products (EMP)
World Health Organization
20 Avenue Appia
CH-1211 Geneva 27
Switzerland

Dear Secretariat,

I am writing to on behalf of the Mt. Gay Mental Hospital in support of the application being made by Dr. Craig Katz and his colleagues at Mount Sinai School of Medicine to have Methylphenidate added to the List of Essential Medications. We have collaborated with them for over 3 years on meeting mental health needs in our own country and see their decision to make this application on behalf of people around the world as showing great initiative and wisdom. We have much experience with Methylphenidate.

We believe that at least one central nervous system stimulant should be considered an essential part of any formulary, and our experience definitely supports that it should be Methylphenidate. I would like to make a special appeal that it be included in its immediate-release formulations.

Respectfully,

A handwritten signature in dark ink, appearing to read 'Doris Keens Douglas'.

Dr. Doris Keens Douglas **MD, MPH**
Senior Registrar
Mt. Gay Psychiatric Hospital

Tel: 1 (473) 440 – 3154/3272 Fax: 1 (473) 435 – 4160 mtgayhsp@health.gov.gd

GMERS MEDICAL COLLEGE & HOSPITAL
Department of Psychiatry, Room No: 204,
2nd Floor, Hospital Building, GOTRI, Vadodara - 390021

29 October 2020

The Secretary of the 22nd Expert Committee on the Selection and Use of
Essential Medicines

Medicine Access and Rational Use (MAR)

Department of Essential Medicines and Health Products (EMI)

World Health Organization

20 Avenue Appia

CH-1211 Geneva 27


Switzerland

Dear Secretariat

I am writing to you on behalf of the GMERS Medical College and Hospital, Gotri, Vadodara, India, in support of the application being made by Dr. Craig Katz and his colleagues at the Mount Sinai School of Medicine to have Methylphenidate added to the List of Essential Medications. We have collaborated with them for over a decade on meeting mental health needs in our own country and see their decision to make this application on behalf of people around the world as showing great initiative and wisdom. We have much experience with Methylphenidate.

We believe that at least one central nervous system stimulant should be considered an essential part of any formulary, and our experience definitely supports that it should be methylphenidate. I would like to make a special appeal that it be included in its immediate-release formulations.

Respectfully,



Dr. Sandip H. Shah
MD (Psychiatry)
Professor and Head
Department of Psychiatry
GMERS Medical College
Gotri, Vadodara.

Dr Sandip H Shah MD

Professor and Head of Department of Psychiatry

GMERS Medical College and Hospital, Gotri, Vadodara, INDIA.

Email – hod.psy.gotri@gmail.com.



MINISTRY OF HEALTH

Third Floor, East Block Building
Belmopan, Belize, Central America.

Phone: 501-822-2325/2363 Fax: 501-822-2942/2055
seniorsecretary@health.gov.bz

October 5, 2020

The Secretary of the 22rd Expert Committee on the
Selection and Use of Essential Medicines
Medicine Access and Rational Use (MAR)
Department of Essential Medicines and Health Products (EMP)
World Health Organization
20 Avenue Appia
CH-LZII Geneva2T
Switzerland

Dear Secretariat,

I am writing to you on behalf of the Ministry of Health, Belize in support of the application being made by Dr. Craig Katz and his colleagues at the Mount Sinai School of Medicine to have Methylphenidate added to the List of Essential Medications. We have collaborated with them for over 10 years on meeting mental health needs in our own country and see their decision to make this application on behalf of people around the world as showing great initiative and wisdom. We have much experience with Methylphenidate.

We believe that at least one central nervous system stimulant should be considered an essential part of any formulary, and our experience definitely supports that it should be Methylphenidate. I would like to make a special appeal that it be included in its immediate-release formulations.

Respectfully,

Iveth Quintanilla, RN, PNP, MHA
Head, Mental Health Unit
Belize Ministry of Health
Belize, Central America

13th November 2020

Dear Prof. Faraone,

On behalf of „Buđenje“ - non profit ADHD organisation from Croatia, I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children.


Yours Sincerely,

Marko Ferek
President



Dear Prof. Faraone:

I am writing to support your application for including methylphenidate on the World Health Organization's List of Essential Medicines for Children. Methylphenidate is a first line treatment for attention deficit hyperactivity disorder (ADHD) in Spain, where around of 80% of the children under medical treatment for ADHD are taking methylphenidate. Excluding methylphenidate from the List of Essential Medicines undermines the confidence of prescribers and the families. Also, this decision impact negatively on the appropriate treatment of children with ADHD. Including methylphenidate on the List of Essential Medicines will improve access to this very effective treatment which, in turn, will improve the quality of life of many children with ADHD and the parents that care for them.

Sincerely, 

Prof. Josep Antoni Ramos Quiroga, MD, PhD
Head of Psychiatry Department
Hospital Universitari Vall d'Hebron
Universitat Autònoma de Barcelona

Chair of the Section Neurodevelopmental Disorders Across Lifespan.
European Psychiatric Association

Pg. Vall d'Hebron, 119-129
08035 Barcelona
Spain

Barcelona, October 14th of 2020